OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Piper Jaffray 27th Annual Healthcare Conference in New York at 8:30 a.m. ET on Wednesday, December 2, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/u46tsbd2.
- Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015. The live and archived webcast will be available at http://www.veracast.com/webcasts/opco/healthcare2015/84203554236.cfm.
Geron management will also be hosting an analyst and investor meeting to discuss imetelstat data presented at the 57th American Society of Hematology (ASH) Annual Meeting:
- The meeting will be held at 7:30 p.m. ET on Saturday, December 5, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/o3ovz2db/lan/en.
Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
